Clinical features and response to therapy in 35 children with mixed-lineage leukemia
| Case and type . | Age, y/sex . | WBC,×109/L . | Initial therapy . | Response . | Additional therapy and response . | Duration of survival, y . |
|---|---|---|---|---|---|---|
| Biphenotypic (B + T + My) | ||||||
| 1 | 17/M | 15 | AML | CR | Alive and in CR | 20.9 |
| 2 | 11/M | 1 | ALL | NR | AML → PR → AML → hypocellular → toxic death | 0.1 |
| Biphenotypic (B + My) | ||||||
| 3 | 14/F | 117 | AML | CR | Relapse → ALL → CR → SCT → toxic death | 1.6 |
| 4 | 16/M | 12 | AML | CR | Alive and in CR | 4.1 |
| 5 | 9/F | 10 | AML | CR | Relapse → 2CDA → CR → auto SCT → relapse → ALL → toxic death | 4.9 |
| 6 | 16/M | 150 | AML | PR | ALL therapy → CR | 2.2 |
| 7 | 1/M | 56 | ALL | CR | Alive and in CR | 12.7 |
| 8 | 6/M | 3 | ALL | CR | Relapse → ALL → CR | 12.3 |
| 9 | 2/F | 15 | ALL | CR (MRD+) | SCT → toxic death | 0.7 |
| 10 | 7/M | 44 | ALL | CR | Relapse → AML → CR → relapse → ALL → NR → Clo → NR | 2.1 |
| 11 | 3/F | 8 | ALL | CR | Alive and in CR | 2.9 |
| 12 | 2/M | 20 | ALL | CR (MRD+) | SCT → alive and in CR | 0.5 |
| Biphenotypic (T + My) | ||||||
| 13 | 2/F | 11 | AML | CR | Relapse → AML → multiple relapses | 5.0 |
| 14 | 8/M | na | AML | CR | Relapse → AML → PR → AML → PR → SCT → CR | 8.5 |
| 15 | 2/F | 44 | AML | CR (MRD+) | SCT → CR | 2.5 |
| 16 | 1/F | 3 | AML | CR (MRD+) | SCT → CR | 2.4 |
| 17 | 12/M | 4 | AML | CR | Alive and in CR | 1.9 |
| 18 | 19/F | 103 | AML | CR | Relapse → AML + auto SCT → CR → toxic death | 1.6 |
| 19 | 12/M | 11 | AML | CR | Relapse → AML → toxic death | 4.3 |
| 20 | 4/F | 40 | AML | PR | ALL → CR | 3.6 |
| 21 | 16/F | 2 | AML | NR | ALL → CR → SCT → toxic death | 0.4 |
| 22 | 1/M | 4 | AML | NR | ALL → NR → ALL → NR → AML → CR → SCT → Relapse | 0.9 |
| 23 | 12/F | 79 | AML | NR | ALL → CR | 2.3 |
| 24 | 16/M | 20 | AML | NR | ALL → CR | 5.8 |
| 25 | 13/M | 49 | AML | NR | ALL → CR | 1.7 |
| 26 | 11/M | 1 | AML | NR | ALL → toxic death | 0.1 |
| 27 | 5/M | 103 | ALL | CR | Relapse → AM → NR | 0.1 |
| 28 | 10/M | 2 | ALL | CR | Relapse → AML → CR → SCT → relapse | 2.1 |
| 29 | 14/M | 5 | ALL | CR | Alive and in CR | 8.5 |
| 30 | 13/M | 43 | ALL | CR | Alive and in CR | 5.7 |
| 31 | 10/M | 41 | AML | NR | ALL → CR | 16.5 |
| 32 | 3/F | 3 | ALL | NR | ALL → CR → relapse → AML → CR → haploBMT → toxic death | 1.4 |
| Bilineal (B + My) | ||||||
| 33 | 12/F | 26 | AML | Hypocellular | Toxic death | 0.1 |
| 34 | 2 days/M | 67 | AML | NR | ALL → CR (MRD+) → SCT → toxic death | 0.4 |
| Undifferentiated acute leukemia | ||||||
| 35 | 15/F | 41 | AML | CR | Relapse → SCT → toxic death | 0.5 |
| Case and type . | Age, y/sex . | WBC,×109/L . | Initial therapy . | Response . | Additional therapy and response . | Duration of survival, y . |
|---|---|---|---|---|---|---|
| Biphenotypic (B + T + My) | ||||||
| 1 | 17/M | 15 | AML | CR | Alive and in CR | 20.9 |
| 2 | 11/M | 1 | ALL | NR | AML → PR → AML → hypocellular → toxic death | 0.1 |
| Biphenotypic (B + My) | ||||||
| 3 | 14/F | 117 | AML | CR | Relapse → ALL → CR → SCT → toxic death | 1.6 |
| 4 | 16/M | 12 | AML | CR | Alive and in CR | 4.1 |
| 5 | 9/F | 10 | AML | CR | Relapse → 2CDA → CR → auto SCT → relapse → ALL → toxic death | 4.9 |
| 6 | 16/M | 150 | AML | PR | ALL therapy → CR | 2.2 |
| 7 | 1/M | 56 | ALL | CR | Alive and in CR | 12.7 |
| 8 | 6/M | 3 | ALL | CR | Relapse → ALL → CR | 12.3 |
| 9 | 2/F | 15 | ALL | CR (MRD+) | SCT → toxic death | 0.7 |
| 10 | 7/M | 44 | ALL | CR | Relapse → AML → CR → relapse → ALL → NR → Clo → NR | 2.1 |
| 11 | 3/F | 8 | ALL | CR | Alive and in CR | 2.9 |
| 12 | 2/M | 20 | ALL | CR (MRD+) | SCT → alive and in CR | 0.5 |
| Biphenotypic (T + My) | ||||||
| 13 | 2/F | 11 | AML | CR | Relapse → AML → multiple relapses | 5.0 |
| 14 | 8/M | na | AML | CR | Relapse → AML → PR → AML → PR → SCT → CR | 8.5 |
| 15 | 2/F | 44 | AML | CR (MRD+) | SCT → CR | 2.5 |
| 16 | 1/F | 3 | AML | CR (MRD+) | SCT → CR | 2.4 |
| 17 | 12/M | 4 | AML | CR | Alive and in CR | 1.9 |
| 18 | 19/F | 103 | AML | CR | Relapse → AML + auto SCT → CR → toxic death | 1.6 |
| 19 | 12/M | 11 | AML | CR | Relapse → AML → toxic death | 4.3 |
| 20 | 4/F | 40 | AML | PR | ALL → CR | 3.6 |
| 21 | 16/F | 2 | AML | NR | ALL → CR → SCT → toxic death | 0.4 |
| 22 | 1/M | 4 | AML | NR | ALL → NR → ALL → NR → AML → CR → SCT → Relapse | 0.9 |
| 23 | 12/F | 79 | AML | NR | ALL → CR | 2.3 |
| 24 | 16/M | 20 | AML | NR | ALL → CR | 5.8 |
| 25 | 13/M | 49 | AML | NR | ALL → CR | 1.7 |
| 26 | 11/M | 1 | AML | NR | ALL → toxic death | 0.1 |
| 27 | 5/M | 103 | ALL | CR | Relapse → AM → NR | 0.1 |
| 28 | 10/M | 2 | ALL | CR | Relapse → AML → CR → SCT → relapse | 2.1 |
| 29 | 14/M | 5 | ALL | CR | Alive and in CR | 8.5 |
| 30 | 13/M | 43 | ALL | CR | Alive and in CR | 5.7 |
| 31 | 10/M | 41 | AML | NR | ALL → CR | 16.5 |
| 32 | 3/F | 3 | ALL | NR | ALL → CR → relapse → AML → CR → haploBMT → toxic death | 1.4 |
| Bilineal (B + My) | ||||||
| 33 | 12/F | 26 | AML | Hypocellular | Toxic death | 0.1 |
| 34 | 2 days/M | 67 | AML | NR | ALL → CR (MRD+) → SCT → toxic death | 0.4 |
| Undifferentiated acute leukemia | ||||||
| 35 | 15/F | 41 | AML | CR | Relapse → SCT → toxic death | 0.5 |
WBC indicates white blood cell count; AML, acute myeloid leukemia; CR, complete remission; PR, partial remission; ALL, acute lymphoblastic leukemia; NR, no response; SCT, stem cell transplantation; 2CDA, cladribine; MRD, minimal residual disease; and Clo, clofarabine.